Key facts
- This page summarizes Sarah Boyce's Form 3 filing for Atrium Therapeutics, Inc..
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 26 Feb 2026, 18:16.
Sarah Boyce - 26 Feb 2026 Form 3 Insider Report for Atrium Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- RNA on Nasdaq
- Reported as of
- 26 Feb 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 26 Feb 2026, 18:16:15 UTC
- Prior SEC filing
- 23 Jan 2026
- Next SEC filing
- 27 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adam Grajewski, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sarah Boyce filed Form 3 for Atrium Therapeutics, Inc. on 26 Feb 2026.
Change
- Previous filing in this sequence was filed on 23 Jan 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001629383
Primary reporting owner
Boyce Sarah
- Relationship
- Director
- Address
- C/O ATRIUM THERAPEUTICS, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO
- Signature
- /s/ Adam Grajewski, Attorney-in-Fact
- Signature date
- 26 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
No ticker
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 265,086
- Date
- 26 Feb 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
Exhibit List - Exhibit 24.1 Power of Attorney